{"id":42989,"date":"2026-07-23T10:00:00","date_gmt":"2026-07-23T08:00:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=9cb2e91648785b5e4a781e81e5536fae"},"modified":"2026-07-23T10:00:00","modified_gmt":"2026-07-23T08:00:00","slug":"innate-pharma-to-participate-in-a-bladder-cancer-panel-at-the-btig-virtual-biotechnology-conference","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=42989","title":{"rendered":"Innate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology Conference"},"content":{"rendered":"<p>MARSEILLE, France--(BUSINESS WIRE)--<a href=\"https:\/\/twitter.com\/hashtag\/Cancer?src=hash\" >#Cancer<\/a>--Regulatory News:<\/p><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260722107103\/en\/1245155\/4\/INNATEvertnoirDS.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260722107103\/en\/1245155\/22\/INNATEvertnoirDS.jpg\" \/><\/a><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260722107103\/en\/1245155\/4\/INNATEvertnoirDS.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260722107103\/en\/1245155\/21\/INNATEvertnoirDS.jpg\" \/><\/a><p>\nInnate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201c<b>Innate<\/b>\u201d or the \u201c<b>Company<\/b>\u201d), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that Sonia Quaratino, EVP Chief Medical Officer of Innate Pharma, will participate in the panel discussion, <i>Changing Treatment Landscape in Bladder Cancer<\/i>, at the BTIG Virtual Biotechnology Conference.<\/p><p>\n<b>BTIG Virtual Biotechnology Conference 2026<\/b><\/p><ul class=\"bwlistdisc\">\n<li>\n<b>Panel discussion:<\/b> <i>Changing Treatment Landscape in Bladder Cancer<\/i><\/li>\n<li>\n<b>Date and time:<\/b> July 28, 2026, 10:30 a.m. EDT \/ 4:30 p.m. CEST<\/li>\n<\/ul><p>\n<b>About Innate Pharma<\/b><\/p><p>\nInnate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise on antibody-engineering and innovative target identification, Innate Pharma is developing innovative and differentiated next generation antibody therapeutics.<\/p><p>\nInnate Pharma is advancing a portfolio of differentiated potential first- and\/or best-in-class assets, focused on areas of high unmet medical need, including IPH4502, a differentiated Nectin4 ADC developed in solid tumors, lacutamab, an anti-KIR3DL2 antibody developed in cutaneous T cell lymphomas and monalizumab, an anti-NKG2A antibody developed in collaboration with AstraZeneca in non-small cell lung cancer (NSCLC).<\/p><p>\nInnate Pharma has established collaborations with leading biopharmaceutical companies, including Sanofi and AstraZeneca, as well as renowned academic and research institutions, to advance innovation in immuno-oncology.<\/p><p>\nHeadquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.<\/p><p>\nLearn more about Innate Pharma at <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.innate-pharma.com%2F&amp;esheet=54575006&amp;newsitemid=20260722107103&amp;lan=en-US&amp;anchor=www.innate-pharma.com&amp;index=1&amp;md5=ce7eaf9d808ace6439668ca821274d62\" rel=\"nofollow\" shape=\"rect\">www.innate-pharma.com<\/a> and follow us on <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Finnate-pharma%2F&amp;esheet=54575006&amp;newsitemid=20260722107103&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=2&amp;md5=a5929fb547d855d05cb68b775eae1d83\" rel=\"nofollow\" shape=\"rect\">LinkedIn<\/a> and <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fx.com%2FInnatePharma&amp;esheet=54575006&amp;newsitemid=20260722107103&amp;lan=en-US&amp;anchor=X&amp;index=3&amp;md5=b1d20d2e5100da61a50908102370eb77\" rel=\"nofollow\" shape=\"rect\">X<\/a>.<\/p><p>\n<b>Information about Innate Pharma shares<\/b><\/p><table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<b>ISIN code<\/b><br\/><b>Ticker code<\/b><br\/><b>LEI<\/b><\/p><\/td><td class=\"bwvertalignt bwpadl5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nFR0010331421<\/p><p class=\"bwcellpmargin\">\nEuronext: IPH Nasdaq: IPHA<\/p><p class=\"bwcellpmargin\">\n9695002Y8420ZB8HJE29<\/p><\/td><\/tr>\n<\/table><p>\n<b>Disclaimer on forward-looking information and risk factors<\/b><\/p><p>\nFor a discussion of risks and uncertainties, please refer to the Risk Factors (\u201cFacteurs de Risque\") section of the Universal Registration Document filed with the French Financial Markets Authority (\u201cAMF\u201d), which is available on the AMF website <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.amf-france.org&amp;esheet=54575006&amp;newsitemid=20260722107103&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.amf-france.org&amp;index=4&amp;md5=6ac5940beb1606a4cf6249d7251a79bd\" rel=\"nofollow\" shape=\"rect\">http:\/\/www.amf-france.org<\/a> or on Innate Pharma\u2019s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (\u201cSEC\u201d), including the Company\u2019s Annual Report on Form 20-F for the year ended December 31, 2025, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company\u2019s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release.<\/p><p>\nThis press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.<\/p><br\/> <b>Contacts<\/b> <br\/><p>\n<b>For more information<\/b><\/p><p>\n<b><span class=\"bwuline\">Investors &amp; Media Relations<\/span><\/b><\/p><p>\n<b>Innate Pharma<\/b><br\/>St\u00e9phanie Cornen\n<br\/><a  href=\"mailto:stephanie.cornen@innate-pharma.fr\" rel=\"nofollow\" shape=\"rect\">stephanie.cornen@innate-pharma.fr<\/a><\/p><p>\n<b>Investor Relations<\/b><br\/><a  href=\"mailto:investors@innate-pharma.fr\" rel=\"nofollow\" shape=\"rect\">investors@innate-pharma.fr<\/a><\/p><p>\n<b>Media<\/b><br\/><a  href=\"mailto:communication@innate-pharma.fr\" rel=\"nofollow\" shape=\"rect\">communication@innate-pharma.fr<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>MARSEILLE, France&#8211;(BUSINESS WIRE)&#8211;#Cancer&#8211;Regulatory News:<br \/>\nInnate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201cInnate\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that &#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-42989","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/42989","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=42989"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/42989\/revisions"}],"predecessor-version":[{"id":42990,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/42989\/revisions\/42990"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=42989"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=42989"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=42989"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}